Clinical TrialApr 22, 2026, 04:12 PM
CervoMed's Neflamapimod Phase 2b Trial Shows Positive Brain Data
AI Summary
CervoMed Inc. announced positive data from its Phase 2b RewinD-LB trial at the 2026 American Academy of Neurology Annual Meeting. The data indicated that neflamapimod, the company's drug candidate, successfully increased basal forebrain volume and functional connectivity in patients suffering from dementia with Lewy bodies. This presentation highlights a significant step in the development of neflamapimod for this neurological condition.
Key Highlights
- Neflamapimod Phase 2b RewinD-LB trial data presented at AAN 2026.
- Trial showed neflamapimod increased basal forebrain volume.
- Also demonstrated improved functional connectivity in Lewy body dementia patients.
Price Impact
More from CRVO